Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeetinder Singh Mahal
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Beta
- 3.04
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- -46.01
Financials
Net Income
$-2.76MEBITDA
$-2.76MFree Cash Flow
$-6.92MEPS (diluted)
$-0.10Shares Outstanding (diluted)
28.70M+16205.1%Operating Expenses
$9.21MCash & Debt
$7.31MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-75.80M | $-3.95 |
| 2024 | $0.00 | $-71.27M | $-4.89 |
| 2023 | $0.00 | $-64.47M | $-6.18 |
| 2022 | $0.00 | $-37.69M | $-10.33 |
| 2021 | $0.00 | $-30.64M | $-26.89 |
| 2020 | $0.00 | $-31.67M | $-183.08 |
| 2019 | $0.00 | $-4.99M | $0.00 |
Valuation
JSPRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Negative
…eutics Announces Commencement of an Offer to Purchase Outstanding Warrants REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $…
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.08 per share
Typical surprise -11.9% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.10 vs $-0.27beat
- Thu, May 14$-0.04 vs $-0.46beat
- Mon, Mar 30$-0.32 vs $-0.79beat
- Mon, Nov 10$-1.13 vs $-1.01miss
- Wed, Aug 13$-1.74 vs $-1.20miss
- Mon, May 12$-1.41 vs $-1.17miss
Estimates and results for JSPR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by JSPR officers and directors.
- Bought
- $7.8m
- Sold
- $106k
17 trades
6 trades
- Ros Matthew Ebought
- Crutcher Patrick Jbought
- Wiggans Thomas Gbought
- Wiggans Thomas Gbought
- Lucas Svetlanabought
- Lucas Svetlanabought
- Martell Ronbought
- Martell Ronbought
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in JSPR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.